Analysis of the impact of immunotherapy efficacy and safety in patients with gastric cancer and liver metastasis

Table 3 Comparison of adverse reactions of immunotherapy in patients with advanced gastric cancer with liver metastasis and no liver metastasis grade 1-2, n (%)

Adverse reaction	Liver metastasis (n = 20)	No liver metastasis grade ≥ 3 (n = 28)	χ2	P value
All events related to treatment	5 (25.0)	7 (25.0)	0.001	0.999
Nausea	4 (20.0)	4 (14.0)	0.274	0.073
Diarrhea	2 (10.0)	3 (11.0)	0.006	0.999
Fever	2 (10.0)	4 (14.0)	0.196	0.999
Peripheral neuropathy	2 (10.0)	4 (14.0)	0.196	0.999
Vomit	5 (25.0)	5 (18.0)	0.361	0.721
Fatigue	4 (20.0)	5 (18.0)	0.035	0.999
Anaemia	1 (5.0)	4 (14.0)	1.078	0.385
Anorexia	2 (10.0)	4 (14.0)	0.196	0.999
Rash	1 (5.0)	2 (7.0)	0.091	0.999
Thrombopenia	2 (10.0)	1 (4.0)	0.823	0.563
Abnormal liver function	2 (10.0)	2 (7.0)	0.125	0.999
Leukopenia	3 (15.0)	4 (14.0)	0.005	0.999